NASDAQ:MRSN - Mersana Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $26.17
Forecasted Upside: 73.06 %
Number of Analysts: 7
Breakdown:
0 Sell Ratings
2 Hold Ratings
5 Buy Ratings
0 Strong Buy Ratings

^$15.12 As of 05/10/2021 03:15 PM ET

▼ -0.3 (-1.95%)

1 month | 3 months | 12 months

Get New Mersana Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for MRSN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRSN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$26.17

▲ +73.06% Upside Potential

This price target is based on 7 analysts offering 12 month price targets for Mersana Therapeutics in the last 3 months. The average price target is $26.17, with a high forecast of $33.00 and a low forecast of $18.00. The average price target represents a 73.06% upside from the last price of $15.12.

Buy

The current consensus among 7 investment analysts is to buy stock in Mersana Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

11/17/2019

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

2/15/2020

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/15/2020

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/13/2020

0 strong buy ratings
5 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

11/11/2020

0 strong buy ratings
5 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

2/9/2021

0 strong buy ratings
5 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/10/2021

0 strong buy ratings
5 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

5/10/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
3/30/2021	Credit Suisse Group	Initiated Coverage	Neutral	$18.00	High	i
12/2/2020	Stifel Nicolaus	Initiated Coverage	Buy	$33.00	High	i
11/9/2020	SVB Leerink	Boost Price Target	Outperform	$25.00 ➝ $28.00	Medium	i Rating by J. Chang at SVB Leerink LLC
9/29/2020	JPMorgan Chase & Co.	Initiated Coverage	Neutral		Medium	i
6/24/2020	BTIG Research	Boost Price Target	Buy	$21.00 ➝ $32.00	Low	i
6/23/2020	HC Wainwright	Reiterated Rating	Buy	$26.00	Low	i Rating by Debjit Chattopadhyay at HC Wainwright
5/28/2020	Robert W. Baird	Boost Price Target	Outperform	$12.00 ➝ $20.00	High	i
5/27/2020	SVB Leerink	Boost Price Target	Outperform	$12.00 ➝ $21.00	High	i
5/27/2020	HC Wainwright	Boost Price Target	Buy	$13.00 ➝ $26.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
4/29/2020	BTIG Research	Initiated Coverage	Buy	$14.00	High	i
3/2/2020	HC Wainwright	Reiterated Rating	Buy	$13.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
2/11/2020	HC Wainwright	Reiterated Rating	Buy	$12.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
1/21/2020	HC Wainwright	Boost Price Target	Buy	$7.00 ➝ $12.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
1/13/2020	Cowen	Reiterated Rating	Buy		High	i
1/10/2020	HC Wainwright	Reiterated Rating	Buy	$7.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
11/7/2019	HC Wainwright	Reiterated Rating	Buy	$7.00	Low	i
6/2/2019	Cowen	Reiterated Rating	Buy		High	i
3/11/2019	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight		High	i
3/8/2019	Robert W. Baird	Set Price Target	Buy	$12.00	High	i Rating by Michael Ulz at Robert W. Baird
1/4/2019	HC Wainwright	Set Price Target	Buy	$14.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
11/28/2018	HC Wainwright	Set Price Target	Buy	$23.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
11/14/2018	HC Wainwright	Set Price Target	Buy	$23.00	Low	i Rating by Debjit Chattopadhyay at HC Wainwright
11/14/2018	SVB Leerink	Upgrade	Market Perform ➝ Outperform		Low	i Rating by J. Chang at SVB Leerink LLC
9/18/2018	Wedbush	Boost Price Target	Outperform	$15.00 ➝ $16.00	High	i
9/17/2018	HC Wainwright	Boost Price Target	Hold ➝ Buy	$11.06 ➝ $23.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
8/16/2018	HC Wainwright	Set Price Target	Buy	$16.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
8/15/2018	Robert W. Baird	Set Price Target	Buy	$20.00	Medium	i Rating by Michael Ulz at Robert W. Baird
7/20/2018	SVB Leerink	Reiterated Rating	Overweight ➝ Market Perform	$61.00	Medium	i Rating by J. Chang at SVB Leerink LLC
7/20/2018	HC Wainwright	Set Price Target	Hold ➝ Buy	$16.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
7/19/2018	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$61.00	High	i Rating by J. Chang at SVB Leerink LLC
6/6/2018	HC Wainwright	Set Price Target	Buy	$33.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
5/15/2018	HC Wainwright	Set Price Target	Buy	$33.00	Medium	i Rating by Debjit Chattopadhyay at HC Wainwright
5/7/2018	Robert W. Baird	Initiated Coverage	Outperform ➝ Outperform	$30.00	High	i
4/25/2018	HC Wainwright	Set Price Target	Buy	$33.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
4/17/2018	HC Wainwright	Set Price Target	Buy	$33.00	Medium	i Rating by Debjit Chattopadhyay at HC Wainwright
4/16/2018	Cowen	Reiterated Rating	Buy		Medium	i
3/29/2018	HC Wainwright	Set Price Target	Buy	$33.00	Medium	i Rating by Debjit Chattopadhyay at HC Wainwright
3/28/2018	SVB Leerink	Reiterated Rating	Outperform		High	i Rating by J. Chang at SVB Leerink LLC
3/19/2018	HC Wainwright	Set Price Target	Buy	$33.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
3/19/2018	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$23.00	High	i
3/2/2018	HC Wainwright	Set Price Target	Buy	$33.00	Medium	i Rating by Debjit Chattopadhyay at HC Wainwright
2/15/2018	HC Wainwright	Initiated Coverage	Buy		Medium	i Rating by D. Chattopadhyay at HC Wainwright
7/24/2017	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$25.00	High	i Rating by D. Nierengarten at Wedbush
7/24/2017	SVB Leerink	Initiated Coverage	Outperform ➝ Outperform	$23.00	High	i Rating by M. Schmidt at SVB Leerink LLC
7/24/2017	JPMorgan Chase & Co.	Initiated Coverage	Overweight ➝ Overweight	$23.00	High	i
7/24/2017	Cowen	Initiated Coverage	Outperform		High	i

(Data available from 5/10/2016 forward)

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma; and XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumors, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. It also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. The company has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $15.12

$14.80

$15.25

50 Day Range

MA: $16.47

$14.91

$18.07

52 Week Range

Now: $15.12

$9.00

$29.09

Volume

13,851 shs

Average Volume

947,931 shs

Market Capitalization

$1.04 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.54

Frequently Asked Questions

What sell-side analysts currently cover shares of Mersana Therapeutics?

The following Wall Street research analysts have issued stock ratings on Mersana Therapeutics in the last year: BTIG Research, Credit Suisse Group AG, HC Wainwright, JPMorgan Chase & Co., Robert W. Baird, Stifel Nicolaus, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for MRSN.

What is the current price target for Mersana Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Mersana Therapeutics in the last year. Their average twelve-month price target is $26.17, suggesting a possible upside of 73.1%. Stifel Nicolaus has the highest price target set, predicting MRSN will reach $33.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $18.00 for Mersana Therapeutics in the next year.
View the latest price targets for MRSN.

What is the current consensus analyst rating for Mersana Therapeutics?

Mersana Therapeutics currently has 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MRSN will outperform the market and that investors should add to their positions of Mersana Therapeutics.
View the latest ratings for MRSN.

What other companies compete with Mersana Therapeutics?

Other companies that are similar to Mersana Therapeutics include Hypera, Arena Pharmaceuticals, Hutchison China MediTech, Agios Pharmaceuticals, Legend Biotech, Apellis Pharmaceuticals, Nektar Therapeutics, Alkermes, InnovAge, Karuna Therapeutics, ACADIA Pharmaceuticals, Insmed, Emergent BioSolutions, Turning Point Therapeutics and Arvinas.

How do I contact Mersana Therapeutics' investor relations team?

Mersana Therapeutics' physical mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company's listed phone number is 617-498-0020 and its investor relations email address is [email protected] The official website for Mersana Therapeutics is www.mersana.com.